Tailored immunogens for rationally designed antibody-based HIV-1 vaccines.
Protective HIV-1 vaccines would require the induction of broadly neutralizing antibodies (bNAbs) to be effective against the vast diversity of circulating viral strains. Three new studies provide in vivo demonstration that rational design of vaccine strategies using engineered and native-like HIV-1 immunogens can be exploited for guiding B-cell evolution towards the genesis of HIV-1 bNAbs.